Phase 3 Trial of Oraxol for Metastatic Breast Cancer Is Fully Enrolled

Phase 3 Trial of Oraxol for Metastatic Breast Cancer Is Fully Enrolled
The Phase 3 trial assessing Athenex's Oraxol — an oral formulation of the chemotherapy paclitaxel — for the treatment of advanced breast cancer has completed its planned patient enrollment. The progression of the study is following the anticipated schedule and the first data is expected to be available in the middle of the year, the company announced. Oraxol is being developed as an alternative approach for treating tumors that are responsive to paclitaxel without the risk of infusion-related adverse reactions. In addition to paclitaxel, Oraxol also contains an inhibitor of a pump that prevents the intestine from properly absorbing chemotherapeutic agents. Inhibiting this pump, HM30181, is expected to increase the absorption of paclitaxel by the gastrointestinal tract, increase its levels in the body, and produce better results. Available clinical data suggests that oral chemotherapy plus HM30181 may yield a better clinical response and tolerability profile than intravenous injections. This is largely attributed to the new oral formulation's improved stability and overall distribution in the body. Oraxol was created under the Orascovery treatment development platform, which aims to develop seve
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.